This article has Open Peer Review reports available.
Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1
© Kwon et al; licensee BioMed Central Ltd. 2010
Received: 10 December 2009
Accepted: 24 July 2010
Published: 24 July 2010
Cinnamomum cassia bark is the outer skin of an evergreen tall tree belonging to the family Lauraceae containing several active components such as essential oils (cinnamic aldehyde and cinnamyl aldehyde), tannin, mucus and carbohydrate. They have various biological functions including anti-oxidant, anti-microbial, anti-inflammation, anti-diabetic and anti-tumor activity. Previously, we have reported that anti-cancer effect of cinnamon extracts is associated with modulation of angiogenesis and effector function of CD8+ T cells. In this study, we further identified that anti-tumor effect of cinnamon extracts is also link with enhanced pro-apoptotic activity by inhibiting the activities NFκB and AP1 in mouse melanoma model.
Water soluble cinnamon extract was obtained and quality of cinnamon extract was evaluated by HPLC (High Performance Liquid Chromatography) analysis. In this study, we tested anti-tumor activity and elucidated action mechanism of cinnamon extract using various types of tumor cell lines including lymphoma, melanoma, cervix cancer and colorectal cancer in vitro and in vivo mouse melanoma model.
Cinnamon extract strongly inhibited tumor cell proliferation in vitro and induced active cell death of tumor cells by up-regulating pro-apoptotic molecules while inhibiting NFκB and AP1 activity and their target genes such as Bcl-2, BcL-xL and survivin. Oral administration of cinnamon extract in melanoma transplantation model significantly inhibited tumor growth with the same mechanism of action observed in vitro.
Our study suggests that anti-tumor effect of cinnamon extracts is directly linked with enhanced pro-apoptotic activity and inhibition of NFκB and AP1 activities and their target genes in vitro and in vivo mouse melanoma model. Hence, further elucidation of active components of cinnamon extract could lead to development of potent anti-tumor agent or complementary and alternative medicine for the treatment of diverse cancers.
Herbal medicines are plant-derived products which have been used as traditional folk medicine and food additives. Recently their medicinal properties are under extensive investigation and become a major part of complementary and alternative medicines (CAMs). Their potency for treating different diseases has been reported including cancer, allergy and diabetes [1–4].
Cinnamomum cassia bark is the outer skin of an evergreen tall tree belonging to the family Lauraceae. Its extracts contain several active components such as essential oils (cinnamic aldehyde and cinnamyl aldehyde), tannin, mucus and carbohydrates [5, 6]. They have various biological functions including anti-oxidant, anti-microbial, anti-inflammation, anti-diabetic effects [7–12], and anti-tumor activity [11, 13]. However, for the development of cinnamon as CAMs for cancer treatment, further studies are necessary such as elucidation of working mechanisms and characterization of active compounds directly linked with anti-tumor activity.
Cancers are the most life-threatening health problems in the world . There have been many trials to treat cancers through modulation of anti-tumor immune response, apoptosis and anti-tumor proteins [15–18]. Tumor cells are generally resistant to apoptosis; hence selective killing of tumor cells by promoting apoptosis pathway is an attractive and effective way for development of anti-cancer agents. NFκB and AP1 constitutively active in many kinds of cancers and play critical roles in tumor development and progression through modulation of their target genes involved in angiogenesis, metastasis and cell survival [19–21].
Recently we have reported that anti-cancer effect of cinnamon extracts is associated with modulation of angiogenesis and effector function of CD8+ T cells . In this study we further identified that anti-tumor effect of cinnamon extracts is also linked with their enhanced pro-apoptotic activity by inhibiting the activities of NFκB and AP1 in mouse melanoma model.
C57BL/6 mice (6~8 weeks, male) were purchased from SLC (Japan) and maintained under specific pathogen-free conditions in an animal facility at the Gwangju Institute of Science and Technology (GIST). All of the animal experiments were approved by the GIST Animal Care and Use Committee.
Preparation of cinnamon extract
Dried Cinnamomum cassia bark (Hwajin Distribution Co., Seoul, Korea) was pulverized and extracted for three hours in a hot water extractor. The extract was filtered and the supernatant was concentrated with a rotary evaporator. The extract was then freeze dried resulting in a powder extract. The powder extract was suspended in sterilized distilled water at appropriate concentrations. As we reported in our previous work , HPLC analysis was performed by comparing the levels of trans-cinnamic acid (Sigma, USA) and cinnamic aldehyde (kindly provided by Dr. Ehren., Germany) as known standards makers for the quality control of composition of cinnamon extract in each experiment. Chromatography was carried out using 1% acetic acid (H20)-MeOH (50: 50 v/v) at room temperature on a Phenomenex Luna 5u C18, 100 A pore size, 250 × 4.60 mm I.D. column. The flow rate of the mobile phase was 2 ml/min. The amount of trans-cinnamic acid and cinnamic aldehyde was about 2.9 (mg/g extract) and 7.9 (mg/g extract) in each extract .
B16F10 and Clone M3 (mouse melanoma cell), Hela (human cervical carcinoma cell) and Caco2 (human epithelial colorectal adenocarcinoma cell) were obtained from the Korean Cell Line Bank (Seoul National University, Korea) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, USA), 100 U/ml penicillin (Sigma) and 100 μg/ml streptomycin (Sigma). To check effects of cinnamon extract in normal cells, primary mouse lymphocytes were isolated and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine, penicillin-streptomycin, nonessential amino acids, sodium pyruvate, vitamins, HEPES and 2-mercaptoethanol.
Cell viability analysis
Cell viability and proliferation were determined with EZ-Cytox Cell Viability Assay Kit (Daeil Labservice, Korea) based on the cleavage of the tetrazolium salt to water-soluble formazan by succinate-tetrazolium reductase. Briefly, cells were treated with cinnamon extract (0.5 mg/ml) or Doxorubicin (Sigma) for indicated time points in 6 well plates. After treatment, cells were transferred into 96 well plates in 100 μl of medium and incubated with 10 μl of Ez-CyTox solution for 5 hours in the 37°C incubator. Then absorbance were measured using the Easy Reader EAR 400 (SLT-Lab Instruments, Austria) at 420~480nm. Data was presented by relative growth inhibition to PBS treated cells.
Cell cycle analysis
The effect on cell division by cinnamon treatment was determined by assessing cellular DNA content using propidium iodide (PI) staining . Briefly, cells were treated with 0.5 mg/ml of cinnamon extract for indicated time periods and then each sample was harvested and fixed in 70% ethanol for 10 hours. After fixation, cells were washed with PBS, treated with 0.5 μg/ml of DNase-free RNase (Sigma) for 20 mins at room temperature and stained with 100 μg/ml of PI in 0.1 M sodium citrate buffer (pH 7.4) for 30 mins at 4°C. Flow cytometric analysis (FACS) was performed with EPICS XL Cytometer (Beckman Coulter) and cell cycle distribution was determined with Expo32 program (Beckman Coulter)
Cells (1 × 106) were treated with cinnamon extract (0.5 mg/ml) for indicated time periods and then resuspended in 1ml of 1× Annexin V binding buffer (BD bioscience). After incubating for 15 mins with 5 μl of Annexin V-PE and 7-ADD, at 25°C in the dark, 400 μl of 1× binding buffer was added to each tube and immediately analyzed by FACS. Cells stained with isotype matched normal IgG used as a control and showed less than 0.2% positive population (data not shown).
B16F10 cells were transfected with AP1- or NFκB-dependent reporter construct that contains repeated copies of NFκB or AP1 response elements. After 18 hours culture in complete media, cells were stimulated with PMA (phorbol 12-myristate 13-acetate) and ionomycin (P+I) for 4 hours in the presence or absence several dose of cinnamon extract from 0.1 mg/ml to 0.5 mg/ml. Luciferase activity measured by dual luciferase assay system (Promega) is expressed relative to expression of the cotransfected Renilla luciferase promoter (phRL-null; Promega) to control for transfection efficiency.
RNA isolation, cDNA synthesis, quantitative RT-PCR and standard RT-PCR
Total RNA was prepared using TRI Reagent (Molecular Research Center) according to the manufacturer's protocol. For reverse transcription, cDNA was generated using 1 μg of total RNA, oligo (dT) primer (Promega) and Improm-II Reverse Transcriptase (Promega) in a total volume of 20 μl. One μl of cDNA was amplified using the following RT-PCR primer sets: L32 (5'-GAGGACCAAGAAGTTCATCAG-3' and 5'-GCACAGTAAGATTTGTTGCAC-3'), BcL-xL (5'-GACAAGGAGATGCAGGTATTGG-3' and 5'-TCCCGTAGAGATCCACAAAAGT-3'), Bcl-2 (5'-ATGCCTTTGTGGAACTATATGGC-3'); Bak (5'-GTGACCTGCTTTTTGGCTGAT-3' and 5'-GGTCTCTACGCAAATTCAGGG-3'); Bax (5'-TGAAGACAGGGGCCTTTTTG-3' and 5'-AATTCGCCGGAGACACTCG-3'); Bim (5'-CCCGGAGATACGGATTGCAC-3' and 5'-GCCTCGCGGTAATCATTTGC-3'); Bad (5'-AAGTCCGATCCCGGAATCC-3' and 5'-GCTCACTCGGCTCAAACTCT-3') and 5'-GGTATGCACCCAGAGTGATGC-3'), and Survivin (5'-CTACCGAGAACGAGCCTGATT-3' and 5'- AGCCTTCCAATTCCTTAAAGCAG-3').
Preparation of nuclear extracts
Cell lines or cells isolated from tumor tissues were washed twice with ice cold PBS and incubated in 1ml of lysis buffer (10 mM Tris/HCl, 3 mM CaCl2, 2 mM MgCl2) containing a protease inhibitor cocktail (Roche) for 10 mins on ice. Then the cells were vortexed gently and incubated in 1ml of NP-40 buffer (10 mM Tris/HCl, 3 mM CaCl2, 2 mM MgCl2, 1% NP-40) for 5 mins at 4°C, and the suspension was centrifuged at 3000 rpm for 10 mins at 4°C. Nuclei was washed with 1ml of Buffer A (20 mM Hepes-KOH, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF), and 100 μl of Buffer C (20 mM Hepes-KOH, 25% Glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 5 mM DTT, 0.5 mM PMSF, 1% Triton X-100) was added to the pellet and vortexed vigorously at 4°C for 10 mins. Nuclear debris was removed by centrifugation at 13000 g for 5 mins. Protein concentrations were determined by the Bradford Assay (Bio-Rad). The nuclear extract was confirmed by immunoblotting with anti-Lamin B and anti-Tubulin beta. For single cell suspension of tumor tissues, tumor tissues from each group was homogeized with homogenizer (Fluko).
Proteins were resolved by 10% (for NFκB and AP1) or 15% (for caspase-3, Bcl2, Bcl-xL, Bad, Bax, Bak, Bim and Sruvivin) SDS-PAGE gels, transferred onto a PVDF membrane (Bio-RAD) and subjected to Western blot analysis using anti-NFκB (Abcam), anti-pc-JUN (SantaCruz), anti-caspases-3 (Abcam), anti-Bcl-2 (Abcam), anti-Bcl-xL (Cell signaling), anti-Survivin (Cell signaling), anti-Bad (Abcam), anti-Bax (Abcam), anti-Bak (Abcam), anti-Bim (Abcam) and peroxidase-conjugated secondary antibodies (DAKO). Proteins were visualized with a chemiluminescence kit (Amersham Bioscience). The levels of Tubulin (anti-tubulin; Santa Cruz), beta-actin (anti-beta-actin; Abcam) and Lamin B (anti-lamin B; SantaCruz) detected by relevant antibodies were monitored as a loading control.
Melanoma induction and anti-tumor assay
Mouse melanoma B16F10 (1 × 106 cells/0.1ml) cells were injected subcutaneously (s.c) into the flanks of C57BL/6 mice (6 weeks old male). One week after the injection, mice were divided into two groups (10 mice/each group) and orally treated with either 10 mg/dose (400 μg/g mouse weight) of cinnamon extract in 100 μl of PBS or same volume of PBS alone as a sham control for 30 days. During the treatment period, the tumor size was measured with vernier calipers every 2 days, and tumor volumes were calculated using the standard formula: width2 × length × 0.52. Mice were sacrificed for further analysis after 30 days of treatment.
DNA fragmentation assay
Genomic DNA isolation was performed with gDNA purification kit (Solgent, Korea). Briefly, mouse tumor tissues from the differentially treated group were collected, pooled, and 5 mg of tumor tissues from each group were transferred. They were dissolved in 300ml of cell lysis buffer with 25 mg of proteinase K for 4 hours at 55°C, and then mixed with 100ml of protein precipitation solution. Then solution was centrifugated at 14000 rpm for 3 mins. After centrifugation, DNAs was precipitated, washed with isopropanol and 70% ethanol. DNA pellets were dissolved in 100 μl of DNA hydration solution. Finally, fragmented DNAs (10 ml) were visualized in 2% agarose gels.
Cells seeded on the glass in 12 well plate were incubated with cinnamon extract for 72 hours, washed with PBS and fixed with 4% paraformaldehyde for 15 mins at RT. Fixed cells were incubated in PBS (pH 7.4) containing 200mg of DNase-free RNase (Sigma) for 30 mins at 37°C and stained with 2 mg/ml of Hoechst for 10 mins at 37°C. Nuclear morphology of the cells was observed under fluorescence microscope.
A two-tailed Student's t-test was employed where P < 0.05 was considered to be statistically significant (*p < 0.05, **p < 0.005, and ***p < 0.001).
Cinnamon extract inhibits tumor cell growth in vitro
Treatment of cinnamon extract induces active cell death of melanoma cells in vitro
Cinnamon extract inhibits the melanoma growth by inhibiting NFκB and AP1
Oral administration of cinnamon extract significantly inhibits melanoma progression in vivo
Anti-tumor effect of cinnamon extract is linked to the reduced levels of NFκB and AP1 in vivo melanoma model
Cinnamon is a herbal plant that has been used for various purposes as forms of dietary intake, oriental medicine and CAMs . However, it is still unclear about the exact action mechanisms of cinnamon and its active components related with diverse biological function. Although various beneficial effects of cinnamon extract have been reported, most studies were performed in vitro culture system without elucidation of mechanism of action in vivo.
In our previous work , we have shown that anti-tumoral effects of cinnamon extract in mouse melanoma is mediated by modulation of angiogenesis and cytotoxic activity of CD8+ T cells. In the present study, we further demonstrated that anti-tumoral effects of cinnamon extract are also linked with the induction of apoptosis in a cancer specific manner. In addition, treatment of cinnamon extract reduced the levels and activities of NFκB and AP1 and their target genes such as Bcl-2 and Bcl-xL. These findings strongly suggest that potent anti-tumoral effects of cinnamon extract are mediated by multiple action mechanisms.
Active induction of apoptosis in a cancer specific manner is an attractive way to cure many types of cancers [31, 32]. Cancers have various strategies to escape from the recognition and elimination by the surveillance of host immune system. These include altered expression of genes and proteins involved in cell survival, death and transformation . Among them, one of common survival strategy of cancer cells is to escape from apoptosis by deregulation of apoptotic genes  or hyper-activation of anti-apoptotic genes . Therefore, cancer specific induction of apoptosis is thought to be a good strategy for cancer treatment. In this study, we demonstrated that treatment of cinnamon extract suppressed melanoma progression in vivo (Figure 4 and 5) and inhibition of tumor cell growth in vitro (Figure 1 and Figure 2) through apoptosis induction. Compared with known anti-cancer drugs (for example, Doxorubicin) , potential benefit of cinnamon extract as a complementary and alternative medicine may contribute to its less cytotoxicity in normal cells (Additional file 1, Figure S1B). To compare cytotoxicity of cinnamon extract with anti-cancer drug (e.g, Doxorubicin), firstly we titrated and decided an optimal concentration of cinnamon extract (CE; 0.5 mg/ml) and Doxorubicin (Dox; 5 μM) [35, 36] that does not induce apoptosis in normal cells. Cinnamon extract and Doxorubicin induced comparable level of apoptosis induction in melanoma cells (CE; 60% and Dox; 70%, respectively) (Additional file 1, Figure S1B). Interestingly, however, compared with cinnamon extract, Doxorubicin showed much higher toxic effect in normal cells (primary mouse lymphocyte) (Additional file 1, Figure S1B). Doxorubicin treatment induced significantly higher levels apoptosis (up to 50%) of normal lymphocyte while cinnamon extract induced marginal effect (about 10%) (Additional file 1, Figure S1B). These results suggest a beneficial effect of cinnamon extract with less cytotoxicity than conventional anti-cancer drug in normal cells while maintains its anti-tumor effect. However, further studies are needed to elucidate mechanism of action and core active compounds of cinnamon extract to induce cancer cell apoptosis without affecting normal cells.
NFκB and AP1 play pivotal roles in tumorigenesis [20, 21, 26]. Interestingly, treatment of cinnamon extract strongly down-regulated the levels and activities of NFκB and AP1 both in melanoma cell line (Figure 3) and in mouse melanoma (Figure 5). NFκB is a major regulator of cell proliferation and cell survival. It inhibits apoptosis while stimulating cell proliferation, metastasis, angiogenesis and inflammation . Anti-apoptotic activities of NFκB is generally mediated by activation of set of genes related with cell survival . Together with NFκB, AP1 has also critical roles in tumorigenesis. It stimulates the expression of anti-apoptotic genes, invasive tumor growth, metastasis and angiogenesis . Bcl-2, BcL-xL and survivin are key anti-apoptotic conductors and are target genes of NFκB and AP1 . Treatment of cinnamon extract significantly down-regulated their mRNA expression and protein levels in tumor cell line (Figure 3D and 3E) and melanoma tissue (Figure 5E and 5F) as well. These results suggest that anti-tumor effect of cinnamon extract is linked with the inhibition of NFκB and AP1 and their target genes involved in tumor cell survival and proliferation. In this study, we demonstrated the anti-tumor effect of cinnamon extract in vivo melanoma model. Although cinnamon extracts increased apoptosis in various cancer cell lines such as lymphoma, cervical cancer and colorectal cancer (Figure 1), in vivo animal studies are necessary to test whether cinnamon extracts have also anti-tumor effects in other types of cancers. In summary, anti-tumor effects of cinnamon extract appear to be mediated by multiple mechanisms. These include inhibition of angiogenesis, potentiating CD8+ T cell cytotoxicity  and apoptosis induction in tumor cells. Collectively, our work suggests the potent anti-tumor effect of cinnamon extract.
Cinnamon extract potently inhibited various tumor cell growths in vitro and suppressed in vivo melanoma progression. Anti-cancer effect of cinnamon extract is mediated by apoptosis induction and blockade of NFκB and AP1. Hence, cinnamon extract could lead to development of potent anti-tumor agent or complementary and alternative medicines for the treatment of diverse cancers.
This work was supported by grants from the BioGreen 21 Program, Rural Development Administration (PJ007054), the Regional Technology Innovation Program of the MOCIE (RTI05-01-01) and by a Systems Biology Infrastructure Establishment Grant provided by GIST in 2010.
- Miller JL, Binns HJ, Brickman WJ: Complementary and Alternative Medicine Use in Children with Type 1 Diabetes: A Pilot Survey of Parents. EXPLORE: The Journal of Science and Healing. 2008, 4 (5): 311-314. 10.1016/j.explore.2008.06.002.View ArticleGoogle Scholar
- Esmonde L, Long AF: Complementary therapy use by persons with multiple sclerosis: Benefits and research priorities. Complementary Therapies in Clinical Practice. 2008, 14 (3): 176-184. 10.1016/j.ctcp.2008.03.001.View ArticlePubMedGoogle Scholar
- Ernst E: Complementary/alternative medicine for disease prevention: The good, the bad and the ugly. Preventive Medicine. 49 (2-3): 77-10.1016/j.ypmed.2009.08.006.Google Scholar
- Längler A, Kaatsch P, Spix C, Seifert G: Complementary and alternative treatment methods in children with cancer. A population based retrospective survey on the prevalence of use in Germany. European Journal of Integrative Medicine. 2008, 1 (Supplement 1): 10-10.1016/j.eujim.2008.08.015.View ArticleGoogle Scholar
- Tanaka T: Chemical studies on plant polyphenols and formation of black tea polyphenols. Yakugaku Zasshi. 2008, 128 (8): 1119-1131. 10.1248/yakushi.128.1119.View ArticlePubMedGoogle Scholar
- Wijesekera RO: Historical overview of the cinnamon industry. CRC critical reviews in food science and nutrition. 1978, 10 (1): 1-30. 10.1080/10408397809527243.View ArticlePubMedGoogle Scholar
- Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA: Cinnamon Improves Glucose and Lipids of People With Type 2 Diabetes. Diabetes Care. 2003, 26 (12): 3215-3218. 10.2337/diacare.26.12.3215.View ArticlePubMedGoogle Scholar
- Kim SH, Hyun SH, Choung SY: Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. Journal of Ethnopharmacology. 2006, 104 (1-2): 119-123. 10.1016/j.jep.2005.08.059.View ArticlePubMedGoogle Scholar
- Lee J-S, Jeon S-M, Park E-M, Huh T-L, Kwon O-S, Lee M-K, Choi M-S: Cinnamate Supplementation Enhances Hepatic Lipid Metabolism and Antioxidant Defense Systems in High Cholesterol-Fed Rats. Journal of Medicinal Food. 2003, 6 (3): 183-191. 10.1089/10966200360716599.View ArticlePubMedGoogle Scholar
- Matan N, Rimkeeree H, Mawson AJ, Chompreeda P, Haruthaithanasan V, Parker M: Antimicrobial activity of cinnamon and clove oils under modified atmosphere conditions. International Journal of Food Microbiology. 2006, 107 (2): 180-185. 10.1016/j.ijfoodmicro.2005.07.007.View ArticlePubMedGoogle Scholar
- Schoene NW, Kelly MA, Polansky MM, Anderson RA: Water-soluble polymeric polyphenols from cinnamon inhibit proliferation and alter cell cycle distribution patterns of hematologic tumor cell lines. Cancer Letters. 2005, 230 (1): 134-140. 10.1016/j.canlet.2004.12.039.View ArticlePubMedGoogle Scholar
- Youn HS, Lee JK, Choi YJ, Saitoh SI, Miyake K, Hwang DH, Lee JY: Cinnamaldehyde suppresses toll-like receptor 4 activation mediated through the inhibition of receptor oligomerization. Biochemical Pharmacology. 2008, 75 (2): 494-502. 10.1016/j.bcp.2007.08.033.View ArticlePubMedGoogle Scholar
- Kamei T, Kumano H, Iwata K, Nariai Y, Matsumoto T: The Effect of a Traditional Chinese Prescription for a Case of Lung Carcinoma. The Journal of Alternative and Complementary Medicine. 2000, 6 (6): 557-559. 10.1089/acm.2000.6.557.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.View ArticlePubMedGoogle Scholar
- Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A: The Transcription Factor Nuclear Factor-kappa B and Cancer. Clinical Oncology. 2007, 19 (2): 154-161. 10.1016/j.clon.2006.11.013.View ArticlePubMedGoogle Scholar
- Cassileth BR: Complementary and alternative cancer medicine. Journal of Clinical Oncology. 1999, 17 (11 SUPPL): 44-52.PubMedGoogle Scholar
- Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002, 2 (10): 727-739. 10.1038/nrc905.View ArticlePubMedGoogle Scholar
- Tascilar M, de Jong FA, Verweij J, Mathijssen RHJ: Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence. Oncologist. 2006, 11 (7): 732-741. 10.1634/theoncologist.11-7-732.View ArticlePubMedGoogle Scholar
- Karin M, Cao Y, Greten FR, Li Z-W: NF-[kappa]B in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2 (4): 301-10.1038/nrc780.View ArticlePubMedGoogle Scholar
- Garg A, Aggarwal BB: Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia. 2002, 16: 1053-1068. 10.1038/sj.leu.2402482.View ArticlePubMedGoogle Scholar
- Jochum W, Passegue E, Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene. 2001, 20 (19 REV. ISS. 2): 2401-2412. 10.1038/sj.onc.1204389.View ArticlePubMedGoogle Scholar
- Kwon H-K, Jeon WK, Hwang J-S, Lee C-G, So J-S, Park J-A, Ko BS, Im S-H: Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells. Cancer letters. 2009, 278 (2): 174-182. 10.1016/j.canlet.2009.01.015.View ArticlePubMedGoogle Scholar
- Taylor IW: A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem. 1980, 28 (9): 1021-1024.View ArticlePubMedGoogle Scholar
- Norberta WS, Meghan AK, Marilyn MP, Richard AA: Water-soluble polymeric polyphenols from cinnamon inhibit proliferation and alter cell cycle distribution patterns of hematologic tumor cell lines. Cancer letters. 2005, 230 (1): 134-140. 10.1016/j.canlet.2004.12.039.View ArticleGoogle Scholar
- Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Molecular Immunology. 2003, 39 (11): 615-647. 10.1016/S0161-5890(02)00252-3.View ArticlePubMedGoogle Scholar
- Karin M, Cao Y, Greten FR, Li Z-W: NF-[kappa]B in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2 (4): 301-310. 10.1038/nrc780.View ArticlePubMedGoogle Scholar
- Karin M, Lin A: NF-[kappa]B at the crossroads of life and death. Nat Immunol. 2002, 3 (3): 221-227. 10.1038/ni0302-221.View ArticlePubMedGoogle Scholar
- Ioannou YA, Chen FW: Quantitation of DNA fragmentation in apoptosis. Nucl Acids Res. 1996, 24 (5): 992-993. 10.1093/nar/24.5.992.View ArticlePubMedPubMed CentralGoogle Scholar
- Stadelmann C, Lassmann H: Detection of apoptosis in tissue sections. Cell and Tissue Research. 2000, 301 (1): 19-31. 10.1007/s004410000203.View ArticlePubMedGoogle Scholar
- Wijesekera RO: Historical overview of the cinnamon industry. CRC critical reviews in food science and nutrition. 1978, 10 (1): 1-10.1080/10408397809527243.View ArticlePubMedGoogle Scholar
- Nicholson DW: From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000, 407 (6805): 810-816. 10.1038/35037747.View ArticlePubMedGoogle Scholar
- Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005, 5 (11): 876-885. 10.1038/nrc1736.View ArticlePubMedGoogle Scholar
- Croce CM: Oncogenes and Cancer. N Engl J Med. 2008, 358 (5): 502-511. 10.1056/NEJMra072367.View ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.View ArticlePubMedGoogle Scholar
- Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B: Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms. Journal of Biological Chemistry. 2004, 279 (24): 25535-25543. 10.1074/jbc.M400944200.View ArticlePubMedGoogle Scholar
- Eliaz RE, Nir S, Marty C, Szoka FC: Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes. Cancer Res. 2004, 64 (2): 711-718. 10.1158/0008-5472.CAN-03-0654.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/392/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.